Black Diamond Therapeutics Announces Changes to Board of Directors

21d ago, source: Nasdaq

CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of ...

Black Diamond Therapeutics Inc.

16d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Stoke Therapeutics CFO Stephen Tulipano Resigns; Thomas Leggett Named Replacement

2d ago, source:

Stoke Therapeutics, Inc. (STOK) on Monday said its Chief Financial Officer Stephen Tulipano is stepping down with effect from May 7.

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

21d ago, source: ADVFN

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined ...

Black Diamond Therapeutics Inc Ordinary Shares

13d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Black Diamond Therapeutics Announces Changes to Board of Directors

20d ago, source: Stockhouse

CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...

Black Diamond Therapeutics Inc.

13d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Black Diamond Therapeutics Inc (BDTX)

29d ago, source: Investing

Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients ...